Differential effects of β-arrestin1 and β-arrestin2 on somatostatin receptors in murine AtT-20 corticotroph tumor cells
- 1 January 2021
- journal article
- research article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 68 (2), 163-170
- https://doi.org/10.1507/endocrj.ej20-0251
Abstract
Autonomous production of adrenocorticotropic hormone (ACTH) from pituitary corticotroph adenomas is the primary cause of Cushing’s disease. Somatostatin receptor, a G protein-coupled receptor (GPCR), types 2 (SSTR2) and 5 (SSTR5) mRNA expression is greater than that of other SSTR subtypes in human corticotroph adenomas. Further, the multiligand SOM230 shows potent effects in decreasing ACTH plasma levels and urinary free cortisol levels in patients with Cushing’s disease. We previously showed that both Sstr2 and Sstr5 mRNA levels were unaffected by SOM230 treatment, suggesting that both receptors might not be downregulated by the agonist. Intracellular molecules, such as β-arrestins, modulate ligand activated-receptor responses. In the present study, we determined regulation of β-arrestin1 and β-arrestin2 by SOM230 and dexamethasone in murine AtT-20 corticotroph tumor cells. In addition, we examined the effects of β-arrestin1 and β-arrestin2 on Sstr mRNA and their protein levels. SOM230 treatment increased β-arrestin1 mRNA levels and did not alter β-arrestin2 mRNA levels. SOM230 treatment could induce β-arrestin1 production in corticotroph tumor cells. Dexamethasone treatment decreased β-arrestin2 mRNA levels. β-arrestin2 knockdown increased proopiomelanocortin, and both Sstr2 and Sstr5 mRNA and their protein levels. The β-arrestin2 knockdown-increased proopiomelanocortin mRNA levels were canceled by SOM230 treatment.Keywords
This publication has 11 references indexed in Scilit:
- Somatostatin receptor ligands in the treatment of acromegalyPituitary, 2017
- Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegalyActa Endocrinologica, 2016
- Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivoMolecular and Cellular Endocrinology, 2014
- Somatostatin system: molecular mechanisms regulating anterior pituitary hormonesJournal of Molecular Endocrinology, 2014
- Somatostatin receptor ligands and resistance to treatment in pituitary adenomasJournal of Molecular Endocrinology, 2014
- β-Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With AcromegalyEndocrinology, 2013
- Intracellular degradation of somatostatin‐14 following somatostatin‐receptor 3‐mediated endocytosis in rat insulinoma cellsThe FEBS Journal, 2008
- Somatostatin and somatostatin receptors in Cushing's diseaseMolecular and Cellular Endocrinology, 2008
- Differential regulation of corticotropin-releasing factor receptor type 1 (CRF1 receptor) mRNA via protein kinase A and mitogen-activated protein kinase pathways in rat anterior pituitary cellsMolecular and Cellular Endocrinology, 2005
- The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5Acta Endocrinologica, 2005